| 12.11 0.35 (2.98%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.19 |
1-year : | 17.74 |
| Resists | First : | 13.01 |
Second : | 15.19 |
| Pivot price | 11.86 |
|||
| Supports | First : | 11.58 |
Second : | 10.69 |
| MAs | MA(5) : | 11.65  |
MA(20) : | 11.73 |
| MA(100) : | 12.62 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 52.5 |
D(3) : | 39.2 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 30.78 | Low : | 10.69 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NVCR ] has closed below upper band by 39.1%. Bollinger Bands are 20.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.22 - 12.31 | 12.31 - 12.37 |
| Low: | 11.58 - 11.67 | 11.67 - 11.74 |
| Close: | 11.99 - 12.13 | 12.13 - 12.24 |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Fri, 05 Dec 2025
NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st
Thu, 04 Dec 2025
NovoCure (NASDAQ:NVCR) Stock Price Up 7% - Time to Buy? - MarketBeat
Wed, 03 Dec 2025
NovoCure Limited $NVCR Shares Purchased by American Century Companies Inc. - MarketBeat
Mon, 01 Dec 2025
Novocure (NVCR) Appoints New CEO Amid Leadership Change - GuruFocus
Mon, 01 Dec 2025
Novocure (NASDAQ: NVCR) elevates President Frank Leonard to CEO as Ashley Cordova resigns - Stock Titan
Wed, 26 Nov 2025
Novocure (NASDAQ: NVCR) to Present at 37th Piper Sandler Healthcare Conference on Dec. 2 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 112 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 82.9 (%) |
| Shares Short | 5,970 (K) |
| Shares Short P.Month | 5,240 (K) |
| EPS | -1.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.04 |
| Profit Margin | -27.7 % |
| Operating Margin | -21.6 % |
| Return on Assets (ttm) | -8.4 % |
| Return on Equity (ttm) | -50.6 % |
| Qtrly Rev. Growth | 7.8 % |
| Gross Profit (p.s.) | 4.33 |
| Sales Per Share | 5.73 |
| EBITDA (p.s.) | -1.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | 25 (M) |
| PE Ratio | -7.53 |
| PEG Ratio | 0 |
| Price to Book value | 3.97 |
| Price to Sales | 2.11 |
| Price to Cash Flow | -39.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|